Live birth rates in the different combinations of the Bologna criteria poor ovarian responders: A validation study

Journal of Assisted Reproduction and Genetics

Volumn 32, Issue 6, 2015, Pages 931-937

  La Marca, Antonio ^a   Grisendi, Valentina ^a   Giulini, Simone ^a   Sighinolfi, Giovanna ^a   Tirelli, Alessandra ^a   Argento, Cindy ^a   Re, Claudia ^a   Tagliasacchi, Daniela ^a   Marsella, Tiziana ^a   Sunkara, Sesh Kamal ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

AFC; AMH; Bologna criteria; Live birth rate; Ovarian reserve; Poor response

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; FERTIPEPTIL; GANIRELIX; LEUPRORELIN; RECOMBINANT FOLLITROPIN; TRIPTORELIN; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; INFERTILITY; LIVE BIRTH; MAJOR CLINICAL STUDY; OOCYTE; OVARIAN RESERVE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; VALIDATION STUDY; BIRTH RATE; DRUG EFFECTS; FACTUAL DATABASE; IN VITRO FERTILIZATION; OOCYTE RETRIEVAL; OVARY; OVULATION INDUCTION; PROCEDURES; TREATMENT OUTCOME;

ADULT; AGE FACTORS; BIRTH RATE; DATABASES, FACTUAL; FEMALE; FERTILIZATION IN VITRO; HUMANS; LIVE BIRTH; OOCYTE RETRIEVAL; OVARIAN RESERVE; OVARY; OVULATION INDUCTION; TREATMENT OUTCOME;

EID: 84943363972     PISSN: 10580468     EISSN: 15737330     Source Type: Journal    
DOI: 10.1007/s10815-015-0476-4     Document Type: Article

References (44)

1. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update. 2014;20(1):124–40.
2. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L. ESHRE working group on POR definition. Hum Reprod. 2011;26(7):1616–24.
3. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC, et al. Anti-mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16(2):113–30.
4. La Marca A, Grisendi V, Giulini S, Argento C, Tirelli A, Dondi G, et al. Individualization of the FSH starting dose in IVF/ICSI cycles using the antral follicle count. J Ovarian Res. 2013;6(1):11.
5. LaMarca A, Dondi G, Sighinolfi G, Giulini S, Papaleo E, Cagnacci A, et al. The ovarian response to controlled stimulation in IVF cycles may be predictive of the age at menopause. Hum Reprod. 2014;29(11):2530–5.
6. Garcia JE, Jones GS, Acosta AA, Wright G. HMG/ hCGfollicularmaturation for oocytes aspiration: phase II, 1981. Fertil Steril. 1983;39:174–9.
7. Raga F, Bonilla-Musoles F, Casan EM, Bonilla F. Recombinant follicle stimulating hormone stimulation in poor responders with normal basal concentrations of follicle stimulating hormone and oestradiol: improved reproductive outcome. Hum Reprod. 1999;14:1431–4.
8. Faber BM, Mayer J, Cox B, Jones D, Toner JP, Oehninger S, et al. Cessation of gonadotropin-releasing hormone agonist therapy combined with high-dose gonadotropin stimulation yields favorable pregnancy results in low responders. Fertil Steril. 1998;69:826–30.
9. Shaker A, Yates R, Flemming R, Coutts J, Jamieson M. Absence of effect of adjuvant growth hormone therapy on follicular responses to exogenous gonadotrophins in women: normal and poor responders. Fertil Steril. 1992;58:919–23.
10. Manzi D, Thorton K, Scott L, Nulsen J. The value of increasing the dose of HMG in women who initially demonstrate a poor response. Fertil Steril. 1994;62:251–6.
11. Yarmolinskaya M, Land J, Dumoulin J, Evers J. High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome. Fertil Steril. 1996;65:961–5.
12. Bancsi LF, Broekmans FJ, Looman CW, Habbema JD, teVelde ER. Impact of repeated antral follicle counts on the prediction of POR in women undergoing in vitro fertilization. Fertil Steril. 2004;81(1): 35–41.
13. Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimullerian hormone/mullerian- inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril. 2004;82:1323–9.
14. Ebner T, Sommergruber M, Moser M, Shebl O, Schreier-Lechner E, Tews G. Basal level of anti-Müllerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod. 2006;21: 2022–6.
15. Lekamge DN, Barry M, Kolo M, Lane M, Gilchrist RB, Tremellen KP. Anti-Müllerian hormone as a predictor of IVF outcome. Reprod BioMed Online. 2007;14:602–10.
16. Sahu B, Oztutrk O, Serhal P, Jayaprakasan K. Do ORTs predict miscarriage in women undergoing assisted reproduction treatment? Eur J Obstet Gynecol Reprod Biol. 2010;153(2):181–4.
17. Younis JS, Jadaon J, Izhaki I, Haddad S, Radin O, Bar-Ami S, et al. A simplemultivariate score could predict ovarian reserve, aswell as pregnancy rate, in infertile women. Fertil Steril. 2010;94(2):655–61.
18. Karande V, Gleicher N. A rational approach to the management of low responders in IVF. Hum Reprod. 1999;14:1744–9.
19. Galey-Fontaine J, Cedrin-Durnerin I, Chaibi R, Massin N, Hugues JN. Age andovarian reserve are distinct predictive factors of cycle outcome in low responders. ReprodBioMedOnline. 2005;10:94–9.
20. Zhen XM, Qiao J, Li R, Wang LN, Liu P. The clinical analysis of POR in in-vitro-fertilization embryo-transfer among Chinese couples. J Assist Reprod Genet. 2008;25:17–22.
21. LaMarca A, Sighinolfi G, Giulini S, Traglia M, Argento C, Sala C, et al. Normal serum concentrations of anti-Müllerian hormone in women with regular menstrual cycles. Reprod BioMed Online. 2010;21(4):463–9.
22. Timeva T, Milachich T, Antonova I, Arabaji T, Shterev A, Omar HA. Correlation between number of retrieved oocytes and pregnancy rate after in vitro fertilization/intracytoplasmic sperm infection. Sci World J. 2006;6:686–90.
23. van der Gaast MH, Eijkemans MJ, van der Net JB, de Boer EJ, Burger CW, van Leeuwen FE, et al. Optimum number of oocytes for a successful first IVF treatment cycle. Reprod BioMed Online. 2006;13:476–80.
24. Hendriks DJ, te Velde ER, Looman CW, Bancsi LF, Broekmans FJ. Expected poorovarian response in predicting cumulative pregnancy rates: a powerful tool. Reprod BioMed Online. 2008;17:727–36.
25. Oudendijk JF, Yarde F, Eijkemans MJ, Broekmans FJ, Broer SL. The poor responder in IVF: is the prognosis always poor?: a systematic review. Hum Reprod Update. 2012;18(1):1–11.
26. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG. 2006;113:1210–7.
27. Papathanasiou A. Implementing the ESHRE ‘poor responder’ criteria in research studies: methodological implications. Hum Reprod. 2014;29(9):1835–8.
28. Venetis CA. The Bologna criteria for POR: the good, the bad and the way forward. Hum Reprod. 2014;29(9):1839–41.
29. Domar A, Gordon K, Garcia-Velasco J, La Marca A, Barriere P, Beligotti F. Understanding the perceptions of and emotional barriers to infertility treatment: a survey in four European countries. Hum Reprod. 2012;27(4):1073–9.
30. Polyzos NP, Nwoye M, Corona R, Blockeel C, Stoop D, Haentjens P, et al. Live birth rates in Bologna poor responders treated with ovarian stimulation for IVF/ICSI. Reprod BioMed Online. 2014;28(4):469–74.
31. Tarlatzis BC, Zepiridis L, Grimbizis G, Bontis J. Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum Reprod Update. 2003;9:61–76.
32. Klinkert ER, Broekmans FJ, Looman CW, Te Velde ER. A poor response in the first in vitro fertilization cycle is not necessarily related to a poor prognosis in subsequent cycles. Fertil Steril. 2004;81(5):1247–53.
33. Moolenaar LM, Mohiuddin S, Munro Davie M, Merrilees MA, Broekmans FJ, Mol BW, et al. High live birth rate in the subsequent IVF cycle after first-cyclepoor response among women with mean age 35 and normal FSH. Reprod BioMed Online. 2013;27:362–6.
34. Broer SL, Mol BW, Hendriks D, Broekmans FJ. The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril. 2009;91(3):705–14.
35. LaMarca A, Nelson SM, Sighinolfi G, Manno M, Baraldi E, Roli L, et al. Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction. Reprod BioMed Online. 2011;22(4):341–9.
36. Holte J, Brodin T, Berglund L, Hadziosmanovic N, Olovsson M, Bergh T. Antral follicle counts are strongly associated with livebirth rates after assisted reproduction, with superior treatment outcome in women with polycystic varies. Fertil Steril. 2011;96:594–9.
37. Iliodromiti S, Kelsey TW, Wu O, Anderson RA, Nelson SM. The predictive accuracy of anti-Müllerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature. Hum Reprod Update. 2014;20(4):560–70.
38. Arce JC, Klein BM, LaMarca A. The rate of high ovarian response in women identified at risk by a high serum AMH level is influenced by the type of gonadotropin. Gynecol Endocrinol. 2014;30(6):444–50.
39. Lukaszuk K, Kunicki M, Liss J, Lukaszuk M, Jakiel G. Use of ovarian reserve parameters for predicting live births in women undergoing in vitro fertilization. Eur J Obstet Gynecol Reprod Biol. 2013;168:173–7.
40. Brodin T, Hadziosmanovic N, Berglund L, Olovsson M, Holte J. Antimüllerian hormone levels are strongly associated with livebirth rates after assisted reproduction. J Clin Endocrinol Metab. 2013;98:1107–14.
41. Khader A, Lloyd SM, McConnachie A, Fleming R, Grisendi V, La Marca A, et al. External validation of anti-Müllerian hormone based prediction of live birth in assisted conception. J Ovarian Res. 2013;6:3.
42. Merhi Z, Zapantis A, Berger DS, Jindal SK. Determining an anti- Mullerian hormone cutoff level to predict clinical pregnancy following in vitro fertilization in women with severely diminished ovarian reserve. J Assist Reprod Genet. 2013;30(10):1361–5.
43. Elter K, Kavak ZN, Gokaslan H, Pekin T. Antral follicle assessment after down-regulation may be a useful tool for predicting pregnancy loss in in vitro fertilization pregnancies. Gynecol Endocrinol. 2005;21:33–7.
44. Gleicher N, Weghofer A, Barad DH. Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severelydiminished ovarian reserve. Fertil Steril. 2010;94:2824–7.